It was a pleasure to meet with Prof. Xavier Montalban (Multiple Sclerosis Centre of Catalonia, Vall d’Hebron, Barcelona Hospital Campus, Spain) to discuss the use of ofatumumab as a treatment option for relapsing multiple sclerosis.
The abstract entitled: ‘Effectiveness and Tolerability of Ofatumumab Versus First-line DMTs in Early RMS Patients: Phase 3b STHENOS Study Design’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021.
- Could you tell us a little about ofatumumab and its mechanism of action? (0:15)
- What are the advantages of ofatumumab compared to current treatment options for relapsing multiple sclerosis (RMS) in adults with active disease? (0:36)
- What have recent clinical trial data taught us about the efficacy and safety of ofatumumab in adults with RMS? (1:15)
Disclosures: Xavier Montalban has received speaking honoraria and/or travel expenses for participation in scientific meetings, and/or has been a steering committee member of clinical trials and/or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of the EAN Congress, Virtual 2021.
Share this Video
Related Videos In Multiple Sclerosis
Simon Faissner, EAN 2023: Safety and efficacy of diroximel fumarate in older patients with multiple sclerosis from the phase III EVOLVE-MS-1 study
Oral diroximel fumarate (DRF) has similar efficacy/safety to dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), but improved GI tolerability. In the from EVOLVE-MS-1 study, safety/efficacy of DRF was assessed in patients with RRMS aged >=55 years. Dr Simon Faissner (Ruhr-University Bochum, Germany) summarizes the take-home messages from his presentation of the results of the study. The abstract ‘EPO-160 […]
Enrique Alvarez, AAN 2023: Disease outcomes with ublituximab in participants with highly active disease from subpopulation analyses of the phase III ULTIMATE I and II studies in participants with relapsing multiple sclerosis
The phase III clinical studies Ultimate I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) discusses the aim, designs and outcomes of these studies as well as the subpopulation analyses […]
Enrique Alvarez, AAN 2023: Ublituximab for participants with relapsing multiple sclerosis
The phase III clinical studies ULTIMATE I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) discusses the unmet needs of this population and the mechanism of action of ublituximab. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!